Clinical Trials through ‘Direct To Patient’ in COVID-19

1
Clinical Trials throughDirect To Patientin
COVID-19
2
Clinical Trials through Direct To Patient in
COVID-19

• The COVID-19 pandemic has taken a toll on the
  entire world affecting various sectors including
  the pharmaceutical industry. Unlike the other
  industries, the pharmaceutical industry has not
  come to a halt because of its need in such
  difficult times but some severe restrictions have
  been imposed. In the wake of this pandemic, some
  ongoing activities have been hampered and one
  such activity is the clinical trials that are
  already in process. As the borders of the
  countries have been sealed and opened from time
  to time and with the number of stakeholders
  associated in the process, maintaining the
  supplies has been difficult. This situation
  demands some strict measures that would help in
  easing out the ongoing clinical trial processes.
• This situation has prevented most subjects from
  visiting the sites to collect the drug samples
  that lead to the dropout rate of subjects and has
  affected the recruitment rate as well. On the
  other hand, some have left the trials halfway.
  Moreover, the risk is higher when there is a need
  for multiple visits and financial prospects are
  affected when there is a stock overage. Taking
  these into consideration there aroused a scope
  for a special feature of IRT that is Direct to
  Patients which has been discussed over years in
  the conferences. That if implemented in a
  situation like this, could give unthinkable
  results.

Read More
3
THANK YOU